What Is SCEMBLIX?

SCEMBLIX treats Ph+ CML in chronic phase for those who have previously taken 2 or more TKIs

SCEMBLIX® (asciminib) tablets is a prescription medicine used to treat adults with:

  • Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs)
    • The effectiveness of SCEMBLIX in patients previously treated with 2 or more TKIs is based on a study that measured major molecular response (MMR) rates. No clinical information is available to show if these patients treated with SCEMBLIX live longer or if their symptoms improve. Ongoing studies exist to find out how SCEMBLIX works over a longer period of time.
It is not known if SCEMBLIX is safe and effective in children.

Some patients struggle with drug resistance or unmanageable side effects

For some people, the journey with Ph+ CML in chronic phase can have its ups and downs. That can be for a number of reasons:

  • Your body does not respond to a medication, which is known as primary drug resistance
  • Your body stops responding to a medication, referred to as secondary drug resistance
  • Side effects become unmanageable, which can make it difficult to stay on track with your treatment

Don’t keep concerns to yourself

If you’re not seeing the results you had expected from your current medication, it’s important to speak up.

You may want to talk with your doctor to see if SCEMBLIX may be right for you. A good way to get the conversation started is by using this Doctor Discussion Guide.

How SCEMBLIX works

SCEMBLIX is the first and only TKI that is thought to bind to a different site within the gene that causes Ph+ CML in chronic phase. Your doctor may refer to this as the myristoyl pocket.

-

Nearly twice as many patients achieved a major molecular response (MMR) at 24 weeks

SCEMBLIX is the first treatment for Ph+ CML in chronic phase to show superior efficacy, such as response rates, vs Bosulif® (bosutinib)* in a clinical trial.

In a clinical study among those who did not respond to or did not tolerate 2 or more prior TKIs for Ph+ CML in chronic phase:

  • Nearly twice as many patients achieved MMR with SCEMBLIX at 24 weeks than with Bosulif. The results were 25% for SCEMBLIX (40 of 157 patients) vs 13% for Bosulif (10 of 76 patients)
Nearly twice as many patients achieved MMR with SCEMBLIX at 24 weeks than with Bosulif® (bosutinib).

-

40% of patients achieved a complete cytogenetic response (CCyR) at 24 weeks

In the same clinical study among patients with Ph+ CML in chronic phase who were previously treated with 2 or more TKIs.

  • 4 out of 10 patients (41 of 103 patients or 40%) achieved CCyR at 24 weeks with SCEMBLIX compared with 2.4 out of 10 patients on Bosulif (15 of 62 patients or 24%)

In this clinical trial, the most common side effects reported (≥20%) in patients treated with SCEMBLIX were nose/throat infections and pain in the muscles, bones, or joints.

*Bosulif is a registered trademark of Pfizer Inc.

4 out of 10 patients (42 of 103 patients or 40.8%) achieved CCyR at 24 weeks with SCEMBLIX compared with 2.5 out of 10 patients on Bosulif (15 of 62 patients or 24.2%)

Talk with your doctor about SCEMBLIX

When you have Ph+ CML in chronic phase, it’s important to be your own advocate. To help you have a productive conversation, download the Doctor Discussion Guide.

Common side effects of SCEMBLIX

The most common side effects of SCEMBLIX include:

  • nose, throat, or sinus (upper respiratory tract) infections
  • muscle, bone, or joint pain
  • tiredness
  • nausea
  • rash
  • diarrhea
  • decreased blood platelet counts, white blood cell counts, and red blood cell counts
  • increased blood fat (triglycerides) levels
  • increased blood creatine kinase levels
  • increased blood liver enzyme levels
  • increased blood pancreas enzyme (amylase and lipase) levels

Your doctor may change your dose, temporarily stop, or permanently stop treatment with SCEMBLIX if you have certain side effects.

SCEMBLIX may cause fertility problems in females. This may affect your ability to have a child. Talk to your doctor if this is a concern for you.

Be sure to review information about the serious and most common side effects of SCEMBLIX. Learn more

How to take SCEMBLIX

If your doctor prescribes SCEMBLIX after you have been treated with 2 prior TKIs, be sure to take the medication exactly as instructed.

Do not eat for at least 2 hours before taking SCEMBLIX and 1 hour after your dose. Learn more about taking SCEMBLIX.